Mayer L, Weskamm LM, Addo MM. Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates. Signal Transduct Target Ther. 2024 Nov 20;9(1):327. doi: 10.1038/s41392-024-02058-x. Mayer et al

Riemann L, Weskamm LM, Mayer L, Odak I, Hammerschmidt S, Sandrock I, Friedrichsen M, Ravens I, Fuss J, Hansen G, Addo MM, Förster R. Blood transcriptome profiling reveals distinct gene networks induced by mRNA vaccination against COVID-19. Eur J Immunol. 2024 Nov;54(11):e2451236. doi: 10.1002/eji.202451236. Epub 2024 Oct 14. Riemann et al

Raadsen MP, Dahlke C, Fathi A, Hardtke S, Klüver M, Krähling V, Gerresheim GK, Mayer L, Mykytyn AZ, Weskamm LM, Zoran T, van Gorp ECM, Sutter G, Becker S, Haagmans BL, Addo MM; MVA-MERS-S_DF-1 Study group. Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial. Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00423-7. doi: 10.1016/S1473-3099(24)00423-7. Raadsen, Dahlke, Fathi et al

Weskamm LM, Tarnow P, Harms C, Huchon M, Raadsen MP, Friedrich M, Rübenacker L, Grüttner C, Garcia MG; MVA-MERS-S-CEF study group; Koch T, Becker S, Sutter G, Lhomme E, Haagmans BL, Fathi A, Blois SM, Dahlke C, Richert L, Addo MM. Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach. iScience. 2024 Jul 8;27(8):110470. doi: 10.1016/j.isci.2024.110470. Weskamm et al

Kobbe R, Rau C, Schulze-Sturm U, Stahl F, Fonseca-Brito L, Diemert A, Lütgehetmann M, Addo MM, Arck P, Weskamm LM. Delayed Induction of Noninflammatory SARS-CoV-2 Spike-Specific IgG4 Antibodies Detected 1 Year After BNT162b2 Vaccination in Children. Pediatr Infect Dis J. 2024 Jul 30. doi: 10.1097/INF.0000000000004488. Epub ahead of print. Kobbe et al

Harrer CE, Mayer L, Fathi A, Lassen S, Ly ML, Zinser ME, Wolf T, Becker S, Sutter G, Dahlke C, Addo MM; MVA-MERS-S Study Group. Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans. J Infect Dis. 2024 Jan 9:jiad612. doi: 10.1093/infdis/jiad612. Epub ahead of print. Harrer and Mayer et al

Mayer L, Weskamm LM, Fathi A, Kono M, Heidepriem J, Krähling V, Mellinghoff SC, Ly ML, Friedrich M, Hardtke S, Borregaard S, Hesterkamp T, Loeffler FF, Volz A, Sutter G, Becker S, Dahlke C, Addo MM. MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans. NPJ Vaccines. 2024 Jan 26;9(1):20. doi: 10.1038/s41541-023-00801-z. Mayer and Weskamm et al

Mellinghoff SC, Robrecht S, Sprute R, Mayer L, Weskamm LM, Dahlke C, Gruell H, Teipel F, Schlößer HA, Siepmann K, Thelen M, Fink AM, Fischer K, Klein F, Addo MM, Kolovou A, Cornely OA, Eichhorst B, Hallek M, Langerbeins P. Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia. Eur J Haematol. 2024 May;112(5):788-793. doi: 10.1111/ejh.14170. Epub 2024 Feb 4. Mellinghoff et al

Addo MM. Think Tbc! An Tuberkulose denken, rechtzeitig diagnostizieren und sachgerecht behandeln. Deutsch. Med. Wochenschr. 2023;148(19):1213-4. Addo

Weskamm LM, Dahlke C, Addo MM. Flow cytometric protocol to characterize human memory B cells directed against SARS-CoV-2 spike protein antigens. STAR Protoc. 2022 Dec 16;3(4):101902. doi: 10.1016/j.xpro.2022.101902. Epub 2022 Nov 15. PMID: 36595922; PMCID: PMC9663734. Weskamm et al

Memenga P, Eitze S, Shamsrizi P, Addo MM, Betsch C. Debunking Misinformation and Communicating Critical Events in Vaccine Trials: Experimental Evidence on Vaccination Intentions in SARS-CoV-2 Pandemic. European Journal of Health Communication. 2022 Sep;3(2): 64–96. Memenga et al

Weskamm LM, Fathi A, Raadsen MP, Mykytyn AZ, Koch T, Spohn M, Friedrich M; MVA-MERS-S Study Group, Haagmans BL, Becker S, Sutter G, Dahlke C, Addo MM. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine. Cell Rep Med. 2022 Jul 19;3(7):100685. doi: 10.1016/j.xcrm.2022.100685. Weskamm et al

Fathi A, Dahlke C, Krähling V, Kupke A, Okba NMA, Raadsen MP, Heidepriem J, Müller MA, Paris G, Lassen S, Klüver M, Volz A, Koch T, Ly ML, Friedrich M, Fux R, Tscherne A, Kalodimou G, Schmiedel S, Corman VM, Hesterkamp T, Drosten C, Loeffler FF, Haagmans BL, Sutter G, Becker S, Addo MM. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome. Nat Commun. 2022 Jul 19;13(1):4182. doi: 10.1038/s41467-022-31557-0. Fathi et al

Mellinghoff SC, Robrecht S, Mayer L, Weskamm LM, Dahlke C, Gruell H, Vanshylla K, Schlösser HA, Thelen M, Fink AM, Fischer K, Klein F, Addo MM, Eichhorst B, Hallek M, Langerbeins P. SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. Leukemia. 2022 Feb;36(2):562-565. doi: 10.1038/s41375-021-01500-1. Mellinghoff et al

Koch T, Fathi A, Addo MM. The COVID-19 Vaccine Landscape. Adv Exp Med Biol. 2021;1318:549-573. doi: 10.1007/978-3-030-63761-3_31. Koch et al

Koch T, Mellinghoff SC, Shamsrizi P, Addo MM, Dahlke C. Correlates of Vaccine-Induced Protection against SARS-CoV-2. Vaccines (Basel). 2021 Mar 10;9(3):238. doi: 10.3390/vaccines9030238. Koch et al

Heidepriem J, Dahlke C, Kobbe R, Santer R, Koch T, Fathi A, Seco BMS, Ly ML, Schmiedel S, Schwinge D, Serna S, Sellrie K, Reichardt NC, Seeberger PH, Addo MM, Loeffler FF, On Behalf Of The Id-Uke Covid-Study Group. Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case Series. Pathogens. 2021 Apr 6;10(4):438. doi: 10.3390/pathogens10040438. Heidepriem et al

Shamsrizi P, Kramer FJ, Addo MM, Fathi A. Characterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial. Vaccines (Basel). 2021 Oct 19;9(10):1208. doi: 10.3390/vaccines9101208. Shamsrizi et al

Fathi A, Addo MM, Dahlke C. Sex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens. Front Immunol. 2021 Jan 8;11:601170. doi: 10.3389/fimmu.2020.601170. Fathi et al

Schultheiß C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, Scholz R, Wieters I, Dahlke C, Tolosa E, Sedding DG, Ciesek S, Addo M, Binder M. Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease. Immunity. 2020 Aug 18;53(2):442-455.e4. doi: 10.1016/j.immuni.2020.06.024. Schultheiß et al

Koch T, Dahlke C, Fathi A, Kupke A, Krähling V, Okba NMA, Halwe S, Rohde C, Eickmann M, Volz A, Hesterkamp T, Jambrecina A, Borregaard S, Ly ML, Zinser ME, Bartels E, Poetsch JSH, Neumann R, Fux R, Schmiedel S, Lohse AW, Haagmans BL, Sutter G, Becker S, Addo MM. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis. 2020 Jul;20(7):827-838. doi: 10.1016/S1473-3099(20)30248-6. Koch et al

Koch T, Rottstegge M, Ruibal P, Gomez-Medina S, Nelson EV, Escudero-Pérez B, Pillny M, Ly ML, Koundouno FR, Bore JA, Magassouba N, Dahlke C, Günther S, Carroll MW, Addo MM, Muñoz-Fontela C. Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins. Viruses. 2020 Aug 20;12(9):915. doi: 10.3390/v12090915. Koch et al

Fathi A, Dahlke C, Addo MM. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Hum Vaccin Immunother. 2019;15(10):2269-2285. doi: 10.1080/21645515.2019.1649532. Fathi et al

Poetsch JH, Dahlke C, Zinser ME, Kasonta R, Lunemann S, Rechtien A, Ly ML, Stubbe HC, Krähling V, Biedenkopf N, Eickmann M, Fehling SK, Olearo F, Strecker T, Sharma P, Lang KS, Lohse AW, Schmiedel S, Becker S; VSV-Ebola Consortium (VEBCON), Addo MM. Detectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans. J Infect Dis. 2019 Jan 29;219(4):556-561. doi: 10.1093/infdis/jiy565. Poetsch et al

Angin M, Fathi A, King M, Ledoux MB, Piechocka-Trocha A, Altfeld M, Addo MM. Acute HIV-1 infection is associated with increased plasma levels of heme oxygenase-1 and presence of heme oxygenase-1-specific regulatory T cells. AIDS. 2017 Mar 13;31(5):635-641. doi: 10.1097/QAD.0000000000001390. Angin et al

Dahlke C, Kasonta R, Lunemann S, Krähling V, Zinser ME, Biedenkopf N, Fehling SK, Ly ML, Rechtien A, Stubbe HC, Olearo F, Borregaard S, Jambrecina A, Stahl F, Strecker T, Eickmann M, Lütgehetmann M, Spohn M, Schmiedel S, Lohse AW, Becker S, Addo MM; VEBCON Consortium. Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. EBioMedicine. 2017 May;19:107-118. doi: 10.1016/j.ebiom.2017.03.045. Dahlke et al

Dahlke C, Lunemann S, Kasonta R, Kreuels B, Schmiedel S, Ly ML, Fehling SK, Strecker T, Becker S, Altfeld M, Sow A, Lohse AW, Muñoz-Fontela C, Addo MM. Comprehensive Characterization of Cellular Immune Responses Following Ebola Virus Infection. J Infect Dis. 2017 Jan 15;215(2):287-292. doi: 10.1093/infdis/jiw508. Dahlke et al

Huttner A, Combescure C, Grillet S, Haks MC, Quinten E, Modoux C, Agnandji ST, Brosnahan J, Dayer JA, Harandi AM, Kaiser L, Medaglini D, Monath T; VEBCON and VSV-EBOVAC Consortia, Roux-Lombard P, Kremsner PG, Ottenhoff TH, Siegrist CA. A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa. Sci Transl Med. 2017 Apr 12;9(385):eaaj1701. doi: 10.1126/scitranslmed.aaj1701. Huttner et al

Rechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, Kasonta R, Zinser M, Stubbe H, Matschl U, Lohse A, Krähling V, Eickmann M, Becker S; VEBCON Consortium, Thiébaut R, Altfeld M, Addo MM. Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Rep. 2017 Aug 29;20(9):2251-2261. doi: 10.1016/j.celrep.2017.08.023. Rechtien et al

Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med. 2016 Apr 28;374(17):1647-60. doi: 10.1056/NEJMoa1502924. Agnandji et al

Addo MM, Altfeld M. Sex-based differences in HIV type 1 pathogenesis. J Infect Dis. 2014 Jul 15;209 Suppl 3(Suppl 3):S86-92. doi: 10.1093/infdis/jiu175. Addo et al

Angin M, Sharma S, King M, Murooka TT, Ghebremichael M, Mempel TR, Walker BD, Bhasin MK, Addo MM. HIV-1 infection impairs regulatory T-cell suppressive capacity on a per-cell basis. J Infect Dis. 2014 Sep 15;210(6):899-903. doi: 10.1093/infdis/jiu188. Angin et al

International HIV Controllers Study. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010 Dec 10;330(6010):1551-7. doi: 10.1126/science.1195271. Link